First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma | Naviance

First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma

First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma

A novel treatment approach using combination immunotherapy before and after surgery shows promise for patients with operable mesothelioma, according to a new study led by investigators at the Centro Oncológico Johns Hopkins Kimmel y su Bloomberg~Instituto Kimmel de Inmunoterapia contra el Cáncer.

APRENDE MÁS

VER TODAS LAS NOTICIAS

Mensajes recientes

How a Division I athlete who never smoked turned his stage 4 ALK+ lung cancer diagnosis into a fight for a cure Solving a 15-Year Mystery: Scientists Discover How Gut Bacteria Toxin Invades Colon Cells to Trigger Cancer Advances in Treating Women’s Bladder Cancer Elena’s Story: Recurrent Brain Cancer After a year of turmoil, cancer researchers see promising signs for mRNA vaccines AI and Mammograms Single Nutrient Fuels Cancer-Fighting Power of T Cells Alcohol and Cancer Risk Colon Cancer Screening: What You Need to Know